Synapse - David Hyman

Results (13)

HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers

Journal Article

Li, B. T.; Michelini, F.; Misale, S.; Cocco, E.; Baldino, L.; Cai, Y.; Shifman, S.; Tu, H. Y.; Myers, M. L.; Xu, C.; more...
Cancer Discovery (2020)

Fulltext@MSK | Save

Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases

Journal Article

Guo, R.; Schreyer, M.; Chang, J. C.; Rothenberg, S. M.; Henry, D.; Cotzia, P.; Kris, M. G.; Rekhtman, N.; Young, R. J.; Hyman, D. M.; more...
JCO Precision Oncology (2019)

Fulltext@MSK | Save

Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers

Meeting Abstract

Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
Journal of Thoracic Oncology (2019)

Fulltext@MSK | Save

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial

Meeting Abstract

Li, B. T.; Shen, R.; Offin, M.; Buonocore, D. J.; Myers, M. L.; Venkatesh, A.; Razavi, P.; Ginsberg, M. S.; Ulaner, G. A.; Solit, D. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden

Journal Article

Benayed, R.; Offin, M.; Mullaney, K.; Sukhadia, P.; Rios, K.; Desmeules, P.; Ptashkin, R.; Won, H.; Chang, J.; Halpenny, D.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers

Meeting Abstract

Li, B. T.; Makker, V.; Buonocore, D. J.; Offin, M. D.; Olah, Z. T.; Panora, E.; Shen, R.; Ho, A. L.; Yaeger, R.; Iyer, G.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays

Meeting Abstract

Benayed, R.; Offin, M. D.; Mullaney, K. A.; Sukhadia, P.; Rios, K. M.; Desmeules, P.; Chang, J. C.; Hyman, D. M.; Berger, M. F.; Zehir, A.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial

Journal Article

Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies

Journal Article

Jordan, E. J.; Kim, H. R.; Arcila, M. E.; Barron, D.; Chakravarty, D.; Gao, J. J.; Chang, M. T.; Ni, A.; Kundra, R.; Jonsson, P.; more...
Cancer Discovery (2017)

Fulltext@MSK | Save

Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection

Meeting Abstract

Jordan, E.; Barron, D.; Schultz, N.; Chakravarty, D.; Kris, M. G.; Rudin, C. M.; Li, B. T.; Yu, H. A.; Drilon, A. E.; Rusch, V. W.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save